auto_awesome
Want to know who else bid on this?
Proposal Forge correlates this contract with the original RFP, the losing bidders, and the next recompete window.
Recipient
Entos Pharmaceuticals Inc.Department
National Research Council CanadaAmount
$10.0M
Province
ABType
C
Agreement Number
956891
Purpose
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 1 clinical trials to establish its safety and immunogenicity in healthy adults.
Entos Pharmaceuticals Inc. × National Research Council Canada
15 grants totalling $62.2M
Industrial Research Assistance Program – Contributions to Firms
1,000 grants totalling $111.3M